Axim Biotechnologies Inc Financials

Axim Biotechnologies Inc (AXIM) reported $40K in total revenue for fiscal year 2023. This represents a 345.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Axim Biotechnologies Inc (AXIM) revenue grew by 345.3% year-over-year, from $9K to $40K in fiscal year 2023.

No, Axim Biotechnologies Inc (AXIM) reported a net income of -$8.1M in fiscal year 2023, with a net profit margin of -20395.0%.

Axim Biotechnologies Inc (AXIM) reported diluted earnings per share of $-0.04 for fiscal year 2023. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Axim Biotechnologies Inc (AXIM) had EBITDA of -$2.3M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

Axim Biotechnologies Inc (AXIM) had an operating margin of -6961.0% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.

Axim Biotechnologies Inc (AXIM) had a net profit margin of -20395.0% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.

Axim Biotechnologies Inc (AXIM) generated -$1.0M in free cash flow during fiscal year 2023. This represents a 49.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Axim Biotechnologies Inc (AXIM) generated -$1.0M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

Axim Biotechnologies Inc (AXIM) had $4.1M in total assets as of fiscal year 2023, including both current and long-term assets.

Axim Biotechnologies Inc (AXIM) invested $0 in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

Axim Biotechnologies Inc (AXIM) invested $125K in research and development during fiscal year 2023.

Axim Biotechnologies Inc (AXIM) had 246M shares outstanding as of fiscal year 2023.

Axim Biotechnologies Inc (AXIM) had a current ratio of 0.03 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

Axim Biotechnologies Inc (AXIM) had a debt-to-equity ratio of -0.64 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

Axim Biotechnologies Inc (AXIM) had a return on assets of -195.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

Axim Biotechnologies Inc (AXIM) has negative shareholder equity of -$7.7M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Axim Biotechnologies Inc (AXIM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Axim Biotechnologies Inc (AXIM) has an earnings quality ratio of 0.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Axim Biotechnologies Inc (AXIM) has an interest coverage ratio of -19.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.

Axim Biotechnologies Inc (AXIM) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.